Literature DB >> 28404532

Cost-effectiveness and cost utility of community screening for glaucoma in urban India.

Denny John1, Rajul Parikh2.   

Abstract

OBJECTIVES: Population-based screening for glaucoma has been demonstrated to be cost-effective if targeted at high-risk groups such as older adults and those with a family history of glaucoma, and through use of a technician for conducting initial assessment rather than a medical specialist. This study attempts to investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding) in the urban areas of India. STUDY
DESIGN: A hypothetical screening programme for both primary open-angle glaucoma and angle-closure disease was built for a population aged between 40 and 69 years in the urban areas of India.
METHODS: Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for the screening pathway were derived from published literature and expert opinion. The glaucoma prevalence rates for urban areas were adapted from the Chennai Glaucoma Study findings. A decision-analytical model using TreeAge Pro 2015 was built to model events, costs and treatment pathways. One-way sensitivity analyses were conducted.
RESULTS: The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated incremental cost-effectiveness ratio (ICER) values being 10,668.68 when compared with no screening programme and would treat an additional 4443 cases and prevent 1790 person-years of blindness over a 10-year period in the urban areas of India. Sensitivity analyses revealed that glaucoma prevalence rates across various age groups, screening uptake rate, follow-up compliance after screening, treatment costs and utility values of health states associated with medical and surgical treatment of glaucoma had an impact on the ICER values of the screening programme.
CONCLUSIONS: In comparison with current practice (i.e. without a screening programme but with some opportunistic case finding), the introduction of a community screening programme for glaucoma for the 40-69 years age group is likely to be relatively cost-effective if implemented in the urban areas of India.
Copyright © 2017 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angle-closure disease; Cost utility; Cost-effectiveness; India; Primary open-angle glaucoma; Urban

Mesh:

Year:  2017        PMID: 28404532     DOI: 10.1016/j.puhe.2017.02.016

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  5 in total

1.  The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review.

Authors:  Christopher J Cadham; Marie Knoll; Luz María Sánchez-Romero; K Michael Cummings; Clifford E Douglas; Alex Liber; David Mendez; Rafael Meza; Ritesh Mistry; Aylin Sertkaya; Nargiz Travis; David T Levy
Journal:  Med Decis Making       Date:  2021-10-25       Impact factor: 2.749

2.  Health care cost and benefits of artificial intelligence-assisted population-based glaucoma screening for the elderly in remote areas of China: a cost-offset analysis.

Authors:  Xuan Xiao; Long Xue; Lin Ye; Hongzheng Li; Yunzhen He
Journal:  BMC Public Health       Date:  2021-06-04       Impact factor: 3.295

3.  Cost-effectiveness of glaucoma screening in cataract camps versus opportunistic and passive screening in urban India: A study protocol.

Authors:  Shalinder Sabherwal; Denny John; Suneeta Dubey; Saptarshi Mukherjee; Geetha R Menon; Atanu Majumdar
Journal:  F1000Res       Date:  2019-01-14

Review 4.  The state of cost-utility analysis in India: A systematic review.

Authors:  Tanu Khurana; Amit Gupta; Hemant Rathi
Journal:  Perspect Clin Res       Date:  2021-07-12

Review 5.  Assessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis.

Authors:  Nicolas Iragorri; Eldon Spackman
Journal:  Public Health Rev       Date:  2018-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.